Skip to main content

Manufacturing Expertise

Baltimore, MD (Camden)
Baltimore, MD (Bayview)
Lansing, MI
Winnipeg, MB (Canada)
Hattiesburg, MS

Manufacturing Expertise: Protecting and Enhancing Life in Every Single Dose

Five manufacturing facilities: 

  • Lansing, MI
  • Winnipeg, Canada
  • Baltimore, MD (Camden Campus)
  • Baltimore, MD (Bayview Campus)
  • Hattiesburg, MS

Established and flexible bulk manufacturing capabilities including: 

  • Eukaryotic, microbial and viral expression 
  • Human and equine derived blood plasma products

Contract manufacturing services 
All phases of drug development from project origin through fill-finish of final product 

Currently producing more than 20 commercial products 

Supported the development of more than 200 clinical candidates for our clients 

Single-use systems for efficiency and purity with minimal risk of product contamination 

Facilities have been audited by multiple regulatory agencies including those in the U.S., Canada, EU, and Japan 

Center for Innovation in Advanced 
Development and Manufacturing (CIADM) 

In June of 2012, Biomedical Advanced Research and Development Authority (BARDA) and Emergent entered a  public-private partnership to establish our Center for Innovation in Advanced Development and Manufacturing (CIADM). The CIADM facilitates advanced development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures and ensures domestic manufacturing surge capacity to address the U.S. government's preparedness priorities and needs.

Bayview Campus (Baltimore, MD facility) 

  • One of three CIADM facilities in the United States 
  • Public private partnership 
  • Developed with support from BARDA 
  • Flexible manufacturing 
  • 64,000 ft2 expansion underway 
  • State-of-the-art commercial-manufacturing capabilities 
  • Surge capacity readiness 
  • Goal: Ability to produce 50 million influenza vaccine doses in 4 months 

Center for Innovation in Advanced 
Development and Manufacturing (CIADM) 

In June of 2012, Biomedical Advanced Research and Development Authority (BARDA) and Emergent entered a  public-private partnership to establish our Center for Innovation in Advanced Development and Manufacturing (CIADM). The CIADM facilitates advanced development of chemical, biological, radiological, and nuclear (CBRN) medical countermeasures and ensures domestic manufacturing surge capacity to address the U.S. government's preparedness priorities and needs.

Bayview Campus (Baltimore, MD facility) 

  • One of three CIADM facilities in the United States 
  • Public private partnership 
  • Developed with support from BARDA 
  • Flexible manufacturing 
  • 64,000 ft2 expansion underway 
  • State-of-the-art commercial-manufacturing capabilities 
  • Surge capacity readiness 
  • Goal: Ability to produce 50 million influenza vaccine doses in 4 months 

Contract Manufacturing Operations (CMO) 

We have a proven track record as a world-class provider of contract manufacturing services for both bulk drug substances and sterile injectable drug products.

Our state-of-the-art single-use Bulk Drug Substance (BDS) facility enables turnkey upstream and downstream support for mammalian, microbial, avian, insect and viral cell lines. For sterile injectable drug products, our service offering includes vials and syringes; liquid and lyophilized products.

We currently produce more than 20 commercial products and have supported the development / manufacture of more than 200 clinical candidates for our clients.

Our Baltimore, MD (Camden Campus) facility has been audited by multiple regulatory agencies including those in the U.S., Canada, EU, and Japan. See our Regulatory page for more details.

Contract Manufacturing Operations (CMO) 

We have a proven track record as a world-class provider of contract manufacturing services for both bulk drug substances and sterile injectable drug products.

Our state-of-the-art single-use Bulk Drug Substance (BDS) facility enables turnkey upstream and downstream support for mammalian, microbial, avian, insect and viral cell lines. For sterile injectable drug products, our service offering includes vials and syringes; liquid and lyophilized products.

We currently produce more than 20 commercial products and have supported the development / manufacture of more than 200 clinical candidates for our clients.

Our Baltimore, MD (Camden Campus) facility has been audited by multiple regulatory agencies including those in the U.S., Canada, EU, and Japan. See our Regulatory page for more details.